Immunome Inc
Research Immunome Inc (IMNM) on Bullrun: market cap USD 2.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMNM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.17B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 73.13M
- Free cash flow-USD 63.87M
Valuation Snapshot
latest market cap is USD 2.17B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.94M | -USD 212.39M | -USD 200.60M | n/a | -2.43 | USD 653.48M | USD 3.86M | USD 634.34M |
| FY2024 | USD 9.04M | -USD 292.96M | -USD 117.97M | n/a | -5 | USD 143.35M | USD 4.83M | USD 181.17M |
| FY2023 | USD 14.02M | -USD 106.81M | -USD 8.40M | n/a | -5.38 | USD 98.68M | USD 1.65M | USD 119.88M |
| FY2022 | USD 0 | -USD 36.90M | -USD 28.94M | n/a | -3.09 | USD 20.32M | USD 291.00K | USD 16.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 2.17B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.43B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 684.57M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 457.21M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 26.80M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 156.95M | n/a | n/a | n/a |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
ETFs that hold Immunome Inc
Immunome Inc is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| WisdomTree BioRevolution UCITS ETF - USD Acc | 2.62% | 0.45% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immunome Inc's market cap?
Immunome Inc's market capitalization is USD 2.17B.
What does Immunome Inc do?
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.